Physician profile
Jared Jaynes
NPI 1356606867
$5,295.12
in general payments reported to CMS, 2019-2025
25 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,478 · 2020: $253 · 2021: $371 · 2022: $368 · 2023: $2,022 · 2024: $396 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $1,324.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,834.23 | 2020-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Johnson & Johnson Surgical Vision, INC. | $1,149.53 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $443.98 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $270.96 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Allergan, INC. | $233.65 | 2019-2021 | |
| Dompe US, INC. | $211.78 | 2019-2025 | Oxervate |
| Oyster Point Pharma, INC. | $191.71 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $152.32 | 2019-2021 | |
| Abbvie INC. | $118.00 | 2022-2023 | |
| Kala Pharmaceuticals, INC. | $101.59 | 2019-2022 | |
| Alcon Vision LLC | $90.82 | 2023-2025 | Clareon, Rocklatan |
| Optos, INC. | $73.08 | 2022 | |
| Biotissue Holdings INC. | $59.71 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $53.88 | 2020-2021 | |
| Rxsight INC | $44.70 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $42.42 | 2023 | Onefit Contact Lens |
| Eyevance Pharmaceuticals LLC | $36.07 | 2022 | |
| Thea Pharma INC. | $30.98 | 2022-2023 | Iyuzeh |
| Ani Pharmaceuticals, INC. | $30.64 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $26.53 | 2023 | |
| Shire North American Group INC | $22.93 | 2019 | |
| Lombart Brothers, INC. | $22.23 | 2025 | Opd-III |
| Mallinckrodt Enterprises LLC | $20.38 | 2019 | |
| Aerie Pharmaceuticals, INC. | $17.93 | 2019 | |
| Alcon Research LLC | $15.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Jaynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.